Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M505644200 on September 13, 2005

J. Biol. Chem., Vol. 280, Issue 46, 38478-38488, November 18, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/46/38478    most recent
M505644200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fan, T.
Right arrow Articles by George, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fan, T.
Right arrow Articles by George, S. R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

A Role for the Distal Carboxyl Tails in Generating the Novel Pharmacology and G Protein Activation Profile of µ and {delta} Opioid Receptor Hetero-oligomers*

Theresa Fan{ddagger}, George Varghese§, Tuan Nguyen{ddagger}, Roderick Tse§, Brian F. O'Dowd{ddagger}§, and Susan R. George, Canada Research Chair in Molecular Neuroscience{ddagger}§¶1

From the Departments of §Pharmacology and Medicine, University of Toronto, Toronto, Ontario M5S 1A8 and {ddagger}The Centre for Addiction and Mental Health, Ontario M5T 1R8, Canada

Opioid receptor pharmacology in vivo has predicted a greater number of receptor subtypes than explained by the profiles of the three cloned opioid receptors, and the functional dependence of the receptors on each other shown in gene-deleted animal models remains unexplained. One mechanism for such findings is the generation of novel signaling complexes by receptor hetero-oligomerization, which we previously showed results in significantly different pharmacology for µ and {delta} receptor hetero-oligomers compared with the individual receptors. In the present study, we show that deltorphin-II is a fully functional agonist of the µ-{delta} heteromer, which induced desensitization and inhibited adenylyl cyclase through a pertussis toxin-insensitive G protein. Activation of the µ-{delta} receptor heteromer resulted in preferential activation of G{alpha}z, illustrated by incorporation of GTP{gamma}35S, whereas activation of the individually expressed µ and {delta} receptors preferentially activated G{alpha}i. The unique pharmacology of the µ-{delta} heteromer was dependent on the reciprocal involvement of the distal carboxyl tails of both receptors, so that truncation of the distal µ receptor carboxyl tail modified the {delta}-selective ligand-binding pocket, and truncation of the {delta} receptor distal carboxyl tail modified the µ-selective binding pocket. The distal carboxyl tails of both receptors also had a significant role in receptor interaction, as evidenced by the reduced ability to co-immunoprecipitate when the carboxyl tails were truncated. The interaction between µ and {delta} receptors occurred constitutively when the receptors were co-expressed, but did not occur when receptor expression was temporally separated, indicating that the hetero-oligomers were generated by a co-translational mechanism.


Received for publication, May 23, 2005 , and in revised form, September 12, 2005.

* The work was supported in part by the U.S. National Institute on Drug Abuse and the Canadian Institutes for Health Research. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 To whom correspondence should be addressed: Medical Sciences Bldg., Rm. 4358, 1 King's College Circle, Toronto, Ontario M5S 1A8, Canada. Tel.: 416-978-3367; Fax: 416-971-2868; E-mail: s.george{at}utoronto.ca.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
W. Walwyn, S. John, M. Maga, C. J. Evans, and T. G. Hales
{delta} Receptors Are Required for Full Inhibitory Coupling of {micro} Receptors to Voltage-Dependent Ca2+ Channels in Dorsal Root Ganglion Neurons
Mol. Pharmacol., July 1, 2009; 76(1): 134 - 143.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
F. M. Decaillot, R. Rozenfeld, A. Gupta, and L. A. Devi
Cell surface targeting of {micro}-{delta} opioid receptor heterodimers by RTP4
PNAS, October 14, 2008; 105(41): 16045 - 16050.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
R. Rozenfeld and L. A. Devi
Receptor heterodimerization leads to a switch in signaling: {beta}-arrestin2-mediated ERK activation by {micro}-{delta} opioid receptor heterodimers
FASEB J, August 1, 2007; 21(10): 2455 - 2465.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement